Nasdaq
$31.62▼ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.08BShares out 65.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 4d agoAfter-hours26.10.21 05:366-KKey event#●●●#●●●
Lakefront Biotherapeutics NVBullish
Lakefront Biotherapeutics announced the completion of its share repurchase program originally initiated on June 9, 2026. Between October 12 and October 16, 2026, the company repurchased 107,804 ordinary shares at an average price of 26.48 EUR, bringing its total treasury share holdings to 1,985,157 shares.…more
$31.62-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Pre-market26.10.15 07:26filed6-KKey event
Lakefront Biotherapeutics NV
Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics. Under the agreement, Lakefront receives an upfront payment of 8 million euros and retains the right to up to 230 million dollars in milestone payments plus royalties. The wind-down of the company's legacy cell therapy activities is now substantially complete.…more
$31.62-0.08%vs prev closeView filingShare - 10.13After-hours26.10.14 05:366-KKey event
Lakefront Biotherapeutics NV
Lakefront Biotherapeutics repurchased 126,322 of its own shares at an average price of 26.26 EUR between October 5 and October 9, 2026, as part of the share repurchase program announced on June 9, 2026. As of the market close on October 9, 2026, the company holds a total of 1,877,353 treasury shares.…more
$31.62-0.08%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoAfter-hours26.10.21 05:01Bullish#●●●#●●●
Lakefront Biotherapeutics Completes Share Repurchase Program
Lakefront Biotherapeutics announced the successful completion of its share repurchase program originally initiated in June. The company acquired an additional 107,804 shares as part of its commitment to enhancing shareholder value.…more
$31.62-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14After-hours26.10.15 05:01
●●●●●●●● ●●●●● ●●●●●●
Lakefront Biotherapeutics has completed the sale of its preclinical CAR-T cell therapy pipeline to Armed Cell Therapeutics. The deal includes an 8 million euro upfront payment and potential milestone payments of up to 230 million dollars.…more
$31.62-0.08%vs prev close - 10.13After-hours26.10.14 05:01
●●●●●●●● ●●●●● ●●●●●●
Lakefront Biotherapeutics has repurchased 126,322 of its own shares as part of its ongoing buyback program. This move reflects the company's commitment to its capital allocation strategy and shareholder value.…more
$31.62-0.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report